title: [Long-term oxygen therapy in France, 2006-2011].
abstract: OBJECTIVE
  The study aimed to describe the main characteristics of people treated with long-term oxygen therapy (LTOT) and the trends between 2006 and 2011 for prevalence and incidence.
  
  
  METHODS
  Data were provided from a sample comprising 1/97 of the permanent beneficiaries of the French health insurance. The sample contains anonymous socio-demographic characteristics and data on health care reimbursements. The analyses were carried out among adults aged 20 years and above who had received benefits on account of LTOT.
  
  
  RESULTS
  In 2011, 2.6% of adults were treated with LTOT, corresponding to around 135,000 people. The crude incidence rate was 0.9‰. The prescription of LTOT included LTOT alone (70%), LTOT associated with assisted ventilation (23%) and LTOT associated with continuous positive airway pressure (7%). About 45% of the patients were supported financially in the long-term illness program of the French Social Security because of severe chronic respiratory failure. Between 2006 and 2011, the age-adjusted prevalence rates increased by 2.9% per year in men and by 6.7% per year in women. The age-adjusted incidence rates remained stable in men (+1.6% per year, P=0.45) but increased in women (+4.7% per year, P=0.04). The median survival was 27 months.
  
  
  CONCLUSIONS
  This analysis of the data demonstrates an increasing burden associated with LTOT in France from 2006 to 2011.
authors.affiliation: Institut de veille sanitaire, 12, rue du Val-d'Osne, 94415 Saint-Maurice cedex, France. Electronic address: c.fuhrman@invs.sante.fr.
authors.forename: C
authors.initials: C
authors.lastname: Fuhrman
authors.affiliation: Institut de veille sanitaire, 12, rue du Val-d'Osne, 94415 Saint-Maurice cedex, France.
authors.forename: M
authors.initials: M
authors.lastname: Boussac-Zarebska
authors.affiliation: Service de pneumologie AP-HP, hôpitaux universitaires Paris-Centre, HIA du Val-de-Grâce, 75005 Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Roche
authors.affiliation: Institut de veille sanitaire, 12, rue du Val-d'Osne, 94415 Saint-Maurice cedex, France.
authors.forename: M-C
authors.initials: MC
authors.lastname: Delmas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D005602:France / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data / Q000639:trends; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000627:therapeutic use; D010102:Oxygen Inhalation Therapy / Q000191:economics / Q000706:statistics & numerical data* / Q000639:trends; D012131:Respiratory Insufficiency / Q000191:economics / Q000453:epidemiology* / Q000628:therapy*; D013997:Time Factors
chemical_list: D010100:Oxygen
keywords: BPCO; COPD; Chronic respiratory failure; Epidemiology; Insuffisance respiratoire chronique; Long-term oxygen therapy; Mortality; Oxygénothérapie de longue durée; Survie; Épidémiologie